Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sonoma Pharmaceuticals (SNOA) EBIT (2016 - 2025)

Sonoma Pharmaceuticals has reported EBIT over the past 16 years, most recently at -$678000.0 for Q4 2025.

  • For Q4 2025, EBIT rose 34.24% year-over-year to -$678000.0; the TTM value through Dec 2025 reached -$2.8 million, up 38.02%, while the annual FY2025 figure was -$3.7 million, 21.08% up from the prior year.
  • EBIT for Q4 2025 was -$678000.0 at Sonoma Pharmaceuticals, down from -$337000.0 in the prior quarter.
  • Over five years, EBIT peaked at -$337000.0 in Q3 2025 and troughed at -$3.1 million in Q1 2022.
  • A 5-year average of -$1.2 million and a median of -$997500.0 in 2021 define the central range for EBIT.
  • Biggest five-year swings in EBIT: tumbled 670.41% in 2021 and later skyrocketed 62.52% in 2023.
  • Year by year, EBIT stood at -$958000.0 in 2021, then plummeted by 91.44% to -$1.8 million in 2022, then soared by 53.98% to -$844000.0 in 2023, then dropped by 22.16% to -$1.0 million in 2024, then soared by 34.24% to -$678000.0 in 2025.
  • Business Quant data shows EBIT for SNOA at -$678000.0 in Q4 2025, -$337000.0 in Q3 2025, and -$1.1 million in Q2 2025.